Nemluvio (Nemolizumab)

Nemolizumab, the active ingredient in Nemluvio, is a monoclonal antibody presented as a subcutaneous formulation for injection use. It is indicated for the treatment of atopic dermatitis and related pruritus in patients who require targeted biologic therapy. It targets the interleukin‑31 (IL‑31) signaling pathway, offering a novel approach to control itch and skin inflammation where conventional therapies have been insufficient.

GNH USA supplies Nemluvio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product handling and regulatory compliance across global markets.

Nemluvio acts on the IL‑31 pathway, a key driver of itch in inflammatory skin disorders. - Atopic dermatitis: reduces itch intensity and improves skin lesions in patients with moderate‑to‑severe disease. - Pruritus associated with atopic dermatitis: provides rapid relief of persistent itching that is unresponsive to topical therapies. - Pruritus of dermatologic origin: helps control severe itching when other treatments have failed.

Common Side Effects: - Injection‑site erythema or pain. - Headache. - Nasopharyngitis. - Upper respiratory tract infection. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions. - Severe infections requiring hospitalization. - Development of anti‑drug antibodies that may reduce efficacy.

Before initiating therapy, clinicians should consider the following precautions: - Assess for active infections: postpone treatment if serious infection is present. - Monitor for signs of hypersensitivity: discontinue if severe allergic reaction occurs. - Evaluate immunocompromised status: weigh benefits against increased infection risk. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as data are limited. - Concomitant live vaccines: avoid administration during treatment. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Nemluvio has a limited interaction profile, but clinicians should be aware of the following: Major Interactions (Avoid): - Live attenuated vaccines: may cause uncontrolled infection; avoid concurrent use. - Known hypersensitivity to any component of the formulation.

Moderate Interactions (Monitor Closely): - Immunosuppressive agents (e.g., systemic corticosteroids, methotrexate): may increase infection risk. - Other biologics targeting cytokine pathways: monitor for additive immunomodulation. - Anticoagulants: injection site bleeding may be prolonged; observe for bruising.